Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
Investing.com -- Mira Pharmaceuticals Inc (NASDAQ:MIRA) stock surged 68.9% on Thursday after the company released promising preclinical data for its pain treatment candidate that outperformed morphine in an animal study.
The clinical-stage pharmaceutical company announced that its oral Mira-55 therapy normalized pain and significantly reduced inflammation, demonstrating superior results compared to injected morphine in an established animal model of inflammatory pain. This marks the first time inflammation was directly measured alongside pain in the company’s Mira-55 program.
According to the study, oral Mira-55 fully restored withdrawal responses to baseline levels and outperformed injected morphine in pain threshold normalization. The treatment also significantly reduced inflammation through a CB2 receptor-mediated mechanism, while morphine showed only partial effects.
"These results highlight the strength of our pipeline and the potential of Mira-55 to become a next-generation, non-opioid therapy," said Erez Aminov, CEO of MIRA. The company noted that Mira-55’s ability to address both inflammation and pain perception offers a differentiated approach that could transform how chronic inflammation-driven pain is managed.
The findings build on previous data showing that injected Mira-55 achieved comparable pain relief to morphine. The global non-opioid pain treatment market was valued at $45.3 billion in 2024 and is projected to reach $70.3 billion by 2030, according to Grand View Research.
Beyond pain management, prior preclinical studies have shown that Mira-55 enhanced memory performance and reduced anxiety-related behavior, suggesting broader potential applications for neurologic and neuropsychiatric disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.